Skip to main content

Why do patients stay in clinical trials?

Dr. Atul Deodhar reports on abstract 2347 (Bimekizumab Treatment Resulted in Patients with Axial Spondyloarthritis Maintaining Their Clinical Responses Over 3 Years: Results from Two Phase 3 Studies and Their Open-Label Extension) presented at the 2025 ACR Convergence meeting in Chicago.

ADD THE FIRST COMMENT

If you are a health practitioner, you may to comment.

Due to the nature of these comment forums, only health practitioners are allowed to comment at this time.

×